创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology: In Situ Surgical Models

  • Categories:Company news
  • Author:InnoModels Biotechnology
  • Origin:InnoModels Biotechnology
  • Time of issue:2024-01-16 15:45
  • Views:

(Summary description)InnoModels Biotechnology has been driving innovation in the biomedical field, and its pioneering in-situ surgical modeling technology is opening up new possibilities for medical training and surgical skill enhancement. This technology is expected to lead the way in the field of surgical training by simulating real surgical environments and providing a highly realistic training platform for medical professionals

InnoModels Biotechnology: In Situ Surgical Models

(Summary description)InnoModels Biotechnology has been driving innovation in the biomedical field, and its pioneering in-situ surgical modeling technology is opening up new possibilities for medical training and surgical skill enhancement. This technology is expected to lead the way in the field of surgical training by simulating real surgical environments and providing a highly realistic training platform for medical professionals

  • Categories:Company news
  • Author:InnoModels Biotechnology
  • Origin:InnoModels Biotechnology
  • Time of issue:2024-01-16 15:45
  • Views:
Information

InnoModels Biotechnology has been driving innovation in the biomedical field, and its pioneering in-situ surgical modeling technology is opening up new possibilities for medical training and surgical skill enhancement. This technology is expected to lead the way in the field of surgical training by simulating real surgical environments and providing a highly realistic training platform for medical professionals.
Introduction to In-situ Surgical Modeling Technology
In-situ surgical modeling is a technology that cultures human or animal tissue cells into the laboratory and performs surgical simulations while maintaining in-situ structure and function. With advanced cell culture and simulation technology, InnoModels Biotechnology has successfully restored surgical scenarios to the laboratory, providing medical professionals with a high-quality training experience.
Key advantages of the technology
1. Real surgical environment restoration:
In-situ surgical modeling technology is capable of restoring the real surgical environment, including the surgical site, instrument use and anatomy. This provides a more realistic training experience for medical professionals and helps improve their surgical skills.

 


2. Multidisciplinary training:
The technology can be used for training in multiple medical fields, including surgery, obstetrics and gynecology, and orthopedics. Medical professionals can choose the appropriate model according to their own field of specialization, realizing the flexibility of multidisciplinary training.
3. Real-time feedback and evaluation:
The in-situ surgical model of InnoModels Biotechnology provides real-time feedback and evaluation function, which helps medical professionals to correct operation errors in time and improve the level of surgical skills.
Future Prospects
As medical technology continues to evolve, InnoModels Biotechnology will continue to invest in innovation in the field of in-situ surgical model technology. In the future, we expect to see more simulations of surgical scenarios and the introduction of more advanced training tools to provide medical professionals with a more comprehensive and efficient training experience.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司